Shanghai RAAS Blood Products Co Ltd
002252.SZ · Health Technology · Biotechnology · CN
3,121 employees · raas-corp.com
About
Shanghai RAAS Blood Products Co., Ltd. generates revenue through the research, development, production, and sale of blood products including human albumin, human immunoglobulin for intravenous injection, and human coagulation factors. The company also distributes Chinese medicine products and foods domestically and internationally. Its primary customers are healthcare providers and distributors within China and overseas markets. The firm's product portfolio focuses on essential blood-derived therapies for medical use. The company's main revenue streams come from the domestic Chinese market and international exports of its blood products. Human albumin and immunoglobulin form the core of its sales, while coagulation factors and other blood-related products contribute to its diversified offerings. Distribution channels include both direct sales to hospitals and partnerships with pharmaceutical distributors. Shanghai RAAS Blood Products Co., Ltd. serves healthcare institutions and medical distributors across China and global markets. Its products are primarily used in hospitals for critical care and treatment of various medical conditions. The firm's focus on blood products positions it as a key supplier in the healthcare sector for essential therapeutic solutions.
Annual results
Reported figures, CNY · revenue down 10.1% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 7.3B | 1.6B | 21.5% | — |
| 2024 | 8.2B | 2.2B | 26.8% | — |
| 2023 | 8.0B | 1.8B | 22.3% | — |
| 2022 | 6.6B | 1.9B | 28.6% | — |
| 2021 | 4.3B | 1.3B | 30.2% | — |
Dividends per share
002252.SZ in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Shanghai RAAS Blood Products Co Ltd are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.